FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891467499> ?p ?o ?g. }

• W2891467499 endingPage "45" @default.
• W2891467499 startingPage "34" @default.
• W2891467499 abstract "Purpose: Alpha 2-adrenergic receptor (α2-ADR) agonists are used clinically for a range of indications including reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Animal experiments show that α2-ADR agonists attenuate the injury-induced Müller cell dedifferentiation by a mechanism that involves activation and regulation of extracellular signal-regulated kinase (ERK) 1/2 leading to transactivation of epidermal growth factor receptors (EGFRs). The purpose of this study was to study and corroborate the activation of this system in human cells.Material and Methods: The human Müller cell line MIO-M1 was treated with the α2A-ADR agonist brimonidine in combination with inhibitors for Src-kinase, EGFR-kinase, matrix metalloproteinase (MMP) as well as small interfering RNAs (siRNAs) for the EGFR. The cells were analyzed using immunocytochemistry, quantitative PCR and western blot techniques.Results: Our results show that human MIO-M1 cells express α2A-ADRs and that stimulation of these receptors caused a robust increase of ERK1/2 and protein kinase B (PKB/AKT) (Thr-308) phosphorylation in MIO-M1 cells. P-ERK1/2 and P-AKT (Thr-308) signaling was mediated by Src-kinase and associated with phosphorylation of tyrosine residue of epidermal growth factor receptor (P-EGFR Y1173). In addition, the agonist caused activation of MMPs. These effects could be blocked by Src-kinase inhibitors (PP1, PP2), EGFR-kinase inhibitor (AG1478), EGFR-siRNA and a MMP inhibitor (GM6001).Conclusion: The results confirm that this human Müller cell line responds to ADR stimulation with phosphorylation of ERK and AKT, which suggests that it is possible to pharmacologically target ADR to modulate the early events in human Müller cell dedifferentiation in a similar fashion as been shown for chicken Müller cells.Abbreviations: CRALBP: cellular retinaldehyde binding protein; EGFR: epidermal growth factor receptor; ERK1/2: extracellular signal-regulated kinase 1/2; GS: glutamine synthetase; GPCR: G protein-coupled receptor; IR: immunoreactivity; MAPK: mitogen-activated protein kinase; MMP: matrix metalloproteinase; P-ERK1/2: phospho-ERK1/2; qRT-PCR: quantitative reverse transcriptase PCR" @default.
• W2891467499 created "2018-09-27" @default.
• W2891467499 creator A5037351715 @default.
• W2891467499 creator A5061957079 @default.
• W2891467499 date "2018-09-10" @default.
• W2891467499 modified "2023-10-18" @default.
• W2891467499 title "Alpha 2-Adrenergic Receptor Agonist Brimonidine Stimulates ERK1/2 and AKT Signaling via Transactivation of EGF Receptors in the Human MIO-M1 Müller Cell Line" @default.
• W2891467499 cites W1577577364 @default.
• W2891467499 cites W1726025741 @default.
• W2891467499 cites W1891938867 @default.
• W2891467499 cites W1895565798 @default.
• W2891467499 cites W1934209312 @default.
• W2891467499 cites W1968625794 @default.
• W2891467499 cites W1969440760 @default.
• W2891467499 cites W1981342210 @default.
• W2891467499 cites W1981493299 @default.
• W2891467499 cites W1985569200 @default.
• W2891467499 cites W2005363728 @default.
• W2891467499 cites W2009036890 @default.
• W2891467499 cites W2022126020 @default.
• W2891467499 cites W2022847745 @default.
• W2891467499 cites W2033053403 @default.
• W2891467499 cites W2038975435 @default.
• W2891467499 cites W2062942585 @default.
• W2891467499 cites W2063504478 @default.
• W2891467499 cites W2071443411 @default.
• W2891467499 cites W2081174698 @default.
• W2891467499 cites W2085174561 @default.
• W2891467499 cites W2088089215 @default.
• W2891467499 cites W2089216837 @default.
• W2891467499 cites W2090895449 @default.
• W2891467499 cites W2095062075 @default.
• W2891467499 cites W2101795926 @default.
• W2891467499 cites W2107277218 @default.
• W2891467499 cites W2109078237 @default.
• W2891467499 cites W2116869556 @default.
• W2891467499 cites W2123190981 @default.
• W2891467499 cites W2131416478 @default.
• W2891467499 cites W2133247927 @default.
• W2891467499 cites W2144891857 @default.
• W2891467499 cites W2158556173 @default.
• W2891467499 cites W2174059881 @default.
• W2891467499 cites W2188485203 @default.
• W2891467499 cites W2411060299 @default.
• W2891467499 cites W2529194187 @default.
• W2891467499 cites W2581355009 @default.
• W2891467499 cites W2737675606 @default.
• W2891467499 cites W4232005894 @default.
• W2891467499 cites W4232995978 @default.
• W2891467499 cites W4298462384 @default.
• W2891467499 doi "https://doi.org/10.1080/02713683.2018.1516783" @default.
• W2891467499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30198788" @default.
• W2891467499 hasPublicationYear "2018" @default.
• W2891467499 type Work @default.
• W2891467499 sameAs 2891467499 @default.
• W2891467499 citedByCount "4" @default.
• W2891467499 countsByYear W28914674992021 @default.
• W2891467499 countsByYear W28914674992022 @default.
• W2891467499 countsByYear W28914674992023 @default.
• W2891467499 crossrefType "journal-article" @default.
• W2891467499 hasAuthorship W2891467499A5037351715 @default.
• W2891467499 hasAuthorship W2891467499A5061957079 @default.
• W2891467499 hasBestOaLocation W28914674991 @default.
• W2891467499 hasConcept C104317684 @default.
• W2891467499 hasConcept C108636557 @default.
• W2891467499 hasConcept C11960822 @default.
• W2891467499 hasConcept C1292079 @default.
• W2891467499 hasConcept C134018914 @default.
• W2891467499 hasConcept C135285700 @default.
• W2891467499 hasConcept C153911025 @default.
• W2891467499 hasConcept C170493617 @default.
• W2891467499 hasConcept C184235292 @default.
• W2891467499 hasConcept C185592680 @default.
• W2891467499 hasConcept C2778938600 @default.
• W2891467499 hasConcept C502942594 @default.
• W2891467499 hasConcept C55493867 @default.
• W2891467499 hasConcept C57074206 @default.
• W2891467499 hasConcept C62478195 @default.
• W2891467499 hasConcept C75217442 @default.
• W2891467499 hasConcept C78976303 @default.
• W2891467499 hasConcept C86339819 @default.
• W2891467499 hasConcept C86803240 @default.
• W2891467499 hasConcept C95444343 @default.
• W2891467499 hasConceptScore W2891467499C104317684 @default.
• W2891467499 hasConceptScore W2891467499C108636557 @default.
• W2891467499 hasConceptScore W2891467499C11960822 @default.
• W2891467499 hasConceptScore W2891467499C1292079 @default.
• W2891467499 hasConceptScore W2891467499C134018914 @default.
• W2891467499 hasConceptScore W2891467499C135285700 @default.
• W2891467499 hasConceptScore W2891467499C153911025 @default.
• W2891467499 hasConceptScore W2891467499C170493617 @default.
• W2891467499 hasConceptScore W2891467499C184235292 @default.
• W2891467499 hasConceptScore W2891467499C185592680 @default.
• W2891467499 hasConceptScore W2891467499C2778938600 @default.
• W2891467499 hasConceptScore W2891467499C502942594 @default.
• W2891467499 hasConceptScore W2891467499C55493867 @default.
• W2891467499 hasConceptScore W2891467499C57074206 @default.
• W2891467499 hasConceptScore W2891467499C62478195 @default.

• next